Industries > Pharma > Biologics Market Trends and Forecasts 2018-2028

Biologics Market Trends and Forecasts 2018-2028

Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies

PUBLISHED: 14 November 2018
PAGES: 303
PRODUCT CODE: PHA0341

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

The global biologics market is estimated to reach $250bn in 2023. The market is expected to grow at a CAGR of 4.8% from 2018 to 2023. In 2017, the monoclonal antibodies submarket held 36.3% share of the global biologics market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 303-page report you will receive 166 charts– all unavailable elsewhere.

The 303-page report provides clear detailed insight into the global biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Biologics Market outlook from 2018-2028

Global Biologics Submarkets analysis and forecast from 2018-2028:
Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents
Monoclonal antibodies (mAbs)
Fusion proteins
Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy
Vaccines

• Analysis and forecast from 2018-2028 for selected leading biologics in the market:
• Lantus
• NovoLog/NovoRapid
• Humalog
• Avonex
• Rebif
• Humira
• Remicade
• Tysabri
• Herceptin
• Kadcyla
• Perjeta
• Enbrel
• Eylea
• OsteoCel Plus
• Trinity Evolution and Trinity Elite
• Apligraf
• Dermagraft
• IMLYGIC

Biologics Market Trends and Forecasts 2018-2028

• This report provides individual revenue forecasts from 2018-2028 for these national markets:
• The US
• Japan
• Germany
• France
• UK
• Italy
• Spain
• China
• India
• Russia
• Brazil

• Our study discusses the selected leading companies that are the major players in the biologics market:
• AbbVie
• Amgen
• AstraZeneca
• Bayer
• Eli Lilly
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis
• Pfizer
• Roche
• Sanofi S.A.

• This report discusses factors that drive and restrain this market. As well as opportunities and trends in this market.

• This report discusses the SWOT and STEP Analysis of the biologics market.

Visiongain’s study is intended for anyone requiring commercial analyses for the biologics market. You find data, trends and predictions.

Buy our report today Biologics Market Trends and Forecasts 2018-2028: Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Biologics Market Trends and Forecasts 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Biologics Market Trends and Forecasts 2018-2028


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category